ThermoDox®

Enhancing the efficacy of doxorubicin with heat-activated liposome technology

GEN-1

Harnessing the potential of IL-12 for targeted immunotherapy treatment

PLACCINE

Celsion Issues Letter to Stockholders and Announces Broad-Based DNA Vaccine Initiative

Novel approaches to enhance the power of proven chemotherapy, immunotherapy, and RNAi agents

ThermoDox®

Enhancing the efficacy of doxorubicin with heat-activated liposome technology

GEN-1

Harnessing the potential of IL-12 for targeted immunotherapy treatment

PLACCINE

Celsion Issues Letter to Stockholders and Announces Broad-Based DNA Vaccine Initiative

Novel approaches to enhance the power of proven chemotherapy, immunotherapy, and RNAi agents

ThermoDox®

Enhancing the efficacy of doxorubicin with heat-activated liposome technology

GEN-1

Harnessing the potential of IL-12 for targeted immunotherapy treatment

PLACCINE

Celsion Issues Letter to Stockholders and Announces Broad-based DNA Vaccine Initiative

Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments

With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsion’s mission is transformational. We seek to combine product technologies with novel targeting strategies to support our ultimate goal of improving survival and providing cures for challenging cancers. ThermoDox®,  a proprietary heat-activated liposomal encapsulation of doxorubicin, is our lead product candidate. ThermoDox is currently being evaluated in the OPTIMA Study, a global phase 3 clinical trial for the treatment of primary liver cancer. Next in our pipeline is GEN-1, a highly promising treatment that incorporates a DNA plasmid encoding IL-12 into a unique nanoparticle delivery system. GEN-1 immunotherapy is currently being evaluated in the phase I/II OVATION 2 Study, in combination with chemotherapy, for newly diagnosed ovarian cancer patients.

TECHNOLOGY

Platform technologies designed to fight and prevent tumor growth

PRODUCTS

Enhancing clinically proven agents in chemotherapy and immunotherapy

PIPELINE

A well-balanced portfolio of preclinical through phase 3 clinical studies

Pipeline of Targeted Therapeutic Agents

Pipeline Graph
Pipeline Graph
Pipeline Graph
Pipeline Graph
Pipeline Graph